Browsing by Author Tan, Eng Huat

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2016Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Ken J; Park, Keunchil; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, The Lancet Oncology, vol.17, 5, 2016,pp 577-589
2017Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Kenneth J.; Paz-Ares, Luis; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, vol.28, 2, 2017,pp 270-277